Nanobiotix S.A.

EPA:NANO.PA

4.45 (EUR) • At close September 18, 2024
Bedrijfsnaam Nanobiotix S.A.
Symbool NANO.PA
Munteenheid EUR
Prijs 4.454
Beurswaarde 209,833,205
Dividendpercentage 0%
52-weken bereik 3.816 - 9.3
Industrie Biotechnology
Sector Healthcare
CEO Mr. Laurent Levy Ph.D.
Website https://www.nanobiotix.com

An error occurred while fetching data.

Over Nanobiotix S.A.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer,

Vergelijkbare Aandelen

Genfit S.A. logo

Genfit S.A.

GNFT.PA

3.95 EUR

Median Technologies SA logo

Median Technologies SA

ALMDT.PA

4.07 EUR

Malin Corporation plc logo

Malin Corporation plc

MLC.IR

6.1 EUR

Cellectis S.A. logo

Cellectis S.A.

ALCLS.PA

2.065 EUR

DBV Technologies S.A. logo

DBV Technologies S.A.

DBV.PA

2.136 EUR

Biosynex SA logo

Biosynex SA

ALBIO.PA

4.335 EUR

MedinCell S.A. logo

MedinCell S.A.

MEDCL.PA

16.3 EUR

UG Healthcare Corporation Limited logo

UG Healthcare Corporation Limited

8K7.SI

0.128 SGD

Amplitude Surgical SA logo

Amplitude Surgical SA

AMPLI.PA

3.42 EUR

Financiële Gegevens

Cijfers zijn in miljoenen (EUR)

Cijfers zijn in miljoenen (EUR)